Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is associated with decreased expression of AP-1 and NF-κB
Author
dc.contributor.author
Parra, Eduardo
Author
dc.contributor.author
Ferreira, Jorge
Author
dc.contributor.author
Sáenz Iturriaga, Leonardo Enrique
Admission date
dc.date.accessioned
2019-01-29T15:36:40Z
Available date
dc.date.available
2019-01-29T15:36:40Z
Publication date
dc.date.issued
2011
Cita de ítem
dc.identifier.citation
International Journal of Molecular Medicine, Volumen 28, Issue 5, 2018, Pages 847-853
Identifier
dc.identifier.issn
11073756
Identifier
dc.identifier.issn
1791244X
Identifier
dc.identifier.other
10.3892/ijmm.2011.745
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/161811
Abstract
dc.description.abstract
Previous studies suggest that the effects of Egr-1 on tumorigenesis are critically dependent on the levels of Egr-1 and the cellular context. For this reason, we examined the effects of blocking the Egr-1 activity by a short interfering RNA (siRNA) against Egr-1 on the expression of nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) signaling in the PC-3 and LNCaP prostate carcinoma cell lines. We observed that the reduction in expression of Egr-1 in PC-3 and LNCaP cells by effects of the siRNA vector resulted in lower cell viability and increased apoptosis at 24 and 120 h after transfection. This reduced cell viability correlated well with a reduced activity of the NF-κB and AP-1 factors. We analyzed the expression and activity of these factors and found that p65 and IκB but not p50 were reduced in the siRNA-treated cells. Similarly, we found that c-Fos but not c-Jun was reduced in the siRNA treated cells. These effects were translated to reduced transcriptional activity of NF-κ